Literature DB >> 25177259

Genetic Association Study of Angiotensin II Receptor Types 1 (A168G) and 2 (T1247G and A5235G) Polymorphisms in Breast Carcinoma among Brazilian Women.

Maria Del Carmen Garcia Molina Wolgien1, Ismael Dale Cotrim Guerreiro da Silva1, Afonso Celso Pinto Nazário1, Clovis Riuche Nakaie2, Silvana Aparecida Alves Correa-Noronha3, Samuel Marcos Ribeiro de Noronha3, Gil Facina1.   

Abstract

BACKGROUND: Many types of cancer are associated with polymorphisms of the renin-angiotensin system. Our aim was to assess possible association between single-nucleotide polymorphisms (SNPs) of the angiotensin II receptor types 1 (A168G), and 2 (T1247G and A5235G) with breast cancer. PATIENTS AND METHODS: 242 participating subjects were genotyped and allocated to case or control groups.
RESULTS: Genotype distribution (in %) was: for AGTR1 (A168G): AA, AG, GG = 61, 30, 09 for cases, and 69, 25, 06 for controls (p = 0.55); for AGTR2 (T1247G): TT, TG, GG = 84, 12, 04 for cases, and 81, 17, 02 for controls (p = 0.45); for AGTR2 (A5235G): AA, AG, GG = 32, 67, 01 for cases, and 53, 28, 19 for controls (p < 0.0001). Women carrying genotypes AA/AG in the intronic region of angiotensin II type 2 receptor had an 11-fold higher risk of breast cancer than GG carriers.
CONCLUSIONS: Many types of cancer have been associated with polymorphisms of the renin-angiotensin system. For SNP A5235G, the GG genotype seems to be protective against breast cancer. The other 2 SNPs showed no association. However, SNPs T1247G and A5235G were associated with at least 1 clinical variable, with G being a predictor of better outcome. The use of SNPs A5235G and T1247G (the latter to a lesser degree) as genetic markers should be considered.

Entities:  

Keywords:  Angiotensin II type 1 receptor; Angiotensin II type 2 receptor; Breast neoplasm; Genetic polymorphisms; Genotyping

Year:  2014        PMID: 25177259      PMCID: PMC4132237          DOI: 10.1159/000363429

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  27 in total

1.  Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression.

Authors:  Boel De Paepe; Valerie M Verstraeten; Christian R De Potter; Gillian R Bullock
Journal:  Histochem Cell Biol       Date:  2001-12-22       Impact factor: 4.304

2.  Axillary recurrence after modified radical mastectomy.

Authors:  A Karanikolić; N Djordjević; S Filipovicz; M Pesić; D Milić; D Budjevac; I Djordjević
Journal:  Acta Chir Iugosl       Date:  2005

3.  AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma.

Authors:  S Marsigliante; L Resta; A Muscella; G P Vinson; A Marzullo; C Storelli
Journal:  Cancer Lett       Date:  1996-12-20       Impact factor: 8.679

4.  Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells.

Authors:  A Muscella; S Greco; M G Elia; C Storelli; S Marsigliante
Journal:  J Endocrinol       Date:  2002-05       Impact factor: 4.286

Review 5.  Angiotensin peptides and lung cancer.

Authors:  Patricia E Gallagher; Katherine Cook; David Soto-Pantoja; Jyotsana Menon; E Ann Tallant
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

6.  Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.

Authors:  Sudeep K Bose; Willietta Gibson; Shailendra Giri; Narender Nath; Carlton D Donald
Journal:  Prostate       Date:  2009-09-01       Impact factor: 4.104

7.  Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.

Authors:  Jaclyn H Neo; Eleanor I Ager; Peter W Angus; Jin Zhu; Chandana B Herath; Christopher Christophi
Journal:  BMC Cancer       Date:  2010-04-10       Impact factor: 4.430

8.  Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women.

Authors:  Silvana Aparecida Alves Corrêa; Samuel Marcos Ribeiro de Noronha; Naiara Correa Nogueira-de-Souza; Cristina Valleta de Carvalho; Ana Maria Massad Costa; José Juvenal Linhares; Mariano Tamura Vieira Gomes; Ismael Dale Cotrim Guerreiro da Silva
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2009-03       Impact factor: 1.636

9.  Association of angiotensin-converting enzyme I gene I/D polymorphism with endometrial but not with ovarian cancer.

Authors:  Silvana Aparecida Alves Correa-Noronha; Samuel Marcos Ribeiro de Noronha; Cheryl Alecrim; Adriana de Carvalho Mesquita; Gabriela Soares da Silva Brito; Michele Gilvana Junqueira; Daniela Batista Leite; Cristina Valletta de Carvalho; Ismael Dale Cotrim Guerreiro da Silva
Journal:  Gynecol Endocrinol       Date:  2012-05-10       Impact factor: 2.260

10.  Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore.

Authors:  Woon-Puay Koh; Jian-Min Yuan; David Van Den Berg; Hin-Peng Lee; Mimi C Yu
Journal:  Carcinogenesis       Date:  2004-10-21       Impact factor: 4.944

View more
  3 in total

Review 1.  Role and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastases.

Authors:  Anukriti Singh; Jessica J Nunes; Bushra Ateeq
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

2.  Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest.

Authors:  Kyoko Oura; Tomoko Tadokoro; Shintaro Fujihara; Asahiro Morishita; Taiga Chiyo; Eri Samukawa; Yoshimi Yamana; Koji Fujita; Teppei Sakamoto; Takako Nomura; Hirohito Yoneyama; Hideki Kobara; Hirohito Mori; Hisakazu Iwama; Keiichi Okano; Yasuyuki Suzuki; Tsutomu Masaki
Journal:  Oncol Rep       Date:  2017-09-20       Impact factor: 3.906

3.  Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.

Authors:  Eri Samukawa; Shintaro Fujihara; Kyoko Oura; Hisakazu Iwama; Yoshimi Yamana; Tomoko Tadokoro; Taiga Chiyo; Kiyoyuki Kobayashi; Asahiro Morishita; Mai Nakahara; Hideki Kobara; Hirohito Mori; Keiichi Okano; Yasuyuki Suzuki; Takashi Himoto; Tsutomu Masaki
Journal:  Int J Oncol       Date:  2017-10-23       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.